BioCentury | Jul 16, 2012
Company News

Emergent BioSolutions, Prokarium deal

...Emergent's Typhella Salmonella-based typhoid vaccine and spi-VEC genetic technology. Prokarium said it plans to combine Typhella...
...that uses attenuated Salmonella, which the company then plans to license. Details were not disclosed. Typhella...
...Emergent acquired spi-VEC, which allows for the oral delivery strain of S. typhi used in Typhella...
BioCentury | Aug 23, 2010
Strategy

The future emerges

...Typhella single-dose, drinkable, live attenuated typhoid vaccine in Phase II testing. The company is developing Typhella...
BioCentury | Sep 5, 2005
Clinical News

Oral typhoid vaccine: Phase II data

...Journal of Infectious Diseases. Emergent BioSolutions Inc. , Gaithersburg, Md. Product: Oral typhoid vaccine ( M01ZH09...
BioCentury | Aug 31, 2005
Clinical News

Emergent Phase II typhoid results

...in 32 healthy volunteers, a new dosing regimen of its live, oral typhoid vaccine ( M01ZH09...
BioCentury | Oct 7, 2002
Clinical News

Micro-Ty typhoid vaccine: Phase I/II

...trial of its Micro-Ty vaccine in 60 adult volunteers. Microscience Ltd. , Berkshire, U.K. Product: Micro-Ty typhoid vaccine...
Items per page:
1 - 5 of 5